Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$7.73 USD
+0.08 (1.05%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $7.73 0.00 (0.00%) 5:42 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.73 USD
+0.08 (1.05%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $7.73 0.00 (0.00%) 5:42 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Zacks News
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
by Zacks Equity Research
Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic have been highlighted in this Screen of The Week article.
Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Adverum Biotechnologies (ADVM), IceCure Medical (ICCM), DarioHealth (DRIO), Energous (WATT) and Virgin Galactic (SPCE).
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 332.3% in Adverum Biotechnologies (ADVM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ginkgo's (DNA) total revenues are likely to have declined in the second quarter, owing to the expected ramp-down of the company's K-12 COVID testing services.
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
by Zacks Equity Research
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
by Zacks Equity Research
Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Geron (GERN) is expected to primarily provide updates regarding the launch of its newly approved hematologic malignancy drug, Rytelo, in the United States when it reports second-quarter earnings.
Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adverum Biotechnologies (ADVM) and Medpace (MEDP) have performed compared to their sector so far this year.
Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Adverum Biotechnologies (ADVM) points to a 290.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
by Zacks Equity Research
Adverum Biotechnologies (ADVM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?
by Zacks Equity Research
Here is how Ligand Pharmaceuticals (LGND) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
PetIQ's (PETQ) first-quarter results are likely to reflect growth in the Product and Services segments of the business.
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adverum Biotechnologies (ADVM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
by Zacks Equity Research
Adverum Biotechnologies (ADVM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
by Zacks Equity Research
Here is how Adverum Biotechnologies (ADVM) and Cigna (CI) have performed compared to their sector so far this year.
How Adverum (ADVM) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Adverum (ADVM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.